Johnson & Johnson’s COVID-19 single-shot vaccination will resume for all adults 18 and older in the U.S., under Emergency Use Authorization (EUA), following a decision from the CDC and FDA.   The decision was based on a recommendation from the U.S. CDC Advisory Committee on Immunization Practices (ACIP), which followed a rigorous evaluation of data relating to a very rare adverse event involving blood clots in combination with low platelet counts (thrombosis with thrombocytopenia) observed...